Risankizumab versus Ustekinumab for Moderate-to-Severe Crohn's Disease.

Laurent Peyrin-Biroulet <a class=“affiliation-link” title=“From the Department of Gastroenterology, INFINY Institute, INSERM NGERE, Centre Hospitalier Régional Universitaire de Nancy, Vandœuvre-lès-Nancy, France (L.P.-B.); the Division of …